The article was published by David Wild, In Vivo, Citeline Commercial.
The article was published by Victoria English, MedNous, Evernow Publishing, www.mednous.com
Watch: Adrenomed tackling huge issue of sepsis By Jim Cornall December 19, 2022 Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Its mission is to rescue vascular integrity in order to save the
“A phenomenal breakthrough is taking shape” An interview with Dr. Rainer Strohmenger, Managing Partner at Wellington Partners (Original interview in German)
by Ian Schofield Executive Summary RedHill’s opaganib has shown “potent inhibition” of the Omicron variant in early studies, while the EMA has found nolinks between the mRNA vaccines and autoimmune hepatitis. Read the full
Andreas Bergman, CSO and Frauke Hein, CBO were interviewed by Maike Telgheder from Handelsblatt. Check out the article (German only) here: Link to Handelsblatt article
Adrenomed was featured in the Deutsche Welle report “On the wave of BioNTech success – is it becoming easier to get financing for innovation?” Check out the video with Andreas Bergmann, CSO, and Frauke Hein,
April 2021, by Stephen Hansen
September 2020, by Cormac Sheridan
By loading the map, you agree to Google's privacy policy.
Learn more
© 2024 AdrenoMed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung | Expanded Access Policy
